Skip to content

Ketamine for depression: all studies

Page 116 of 178: studies 1,151 to 1,160 of 1,775, newest first. Back to the ketamine for depression overview

Research

Neuroimaging-Derived Biomarkers of the Antidepressant Effects of Ketamine

Biological Psychiatry: Cognitive Neuroscience and Neuroimaging November 25, 2022 Artemis Zavaliangos-Petropulu, Noor B. Al-Sharif, Brandon Taraku et al. 27 citations

Major depressive disorder is a highly prevalent psychiatric disorder. Despite an extensive range of treatment options, about a third of patients still struggle to respond to available therapies. In the last 20 years, ketamine has gained considerable attention in the psychiatric field as a promising treatment of depression, particularly in patients who are treatment resistant or at high risk for...

The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine

International Journal of Molecular Sciences November 23, 2022 Alina Wilkowska, Wiesław Jerzy Cubała 17 citations

Treatment-resistant depression is a pleomorphic phenomenon occurring in 30% of patients with depression. The chance to achieve remission decreases with every subsequent episode. It constitutes a significant part of the global disease burden, causes increased morbidity and mortality, and is associated with poor quality of life. It involves multiple difficult-to-treat episodes, with increasing...

A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential

Frontiers in Psychiatry November 17, 2022 Brittany Chubbs, Jay Wang, S. Archer et al.

Ketamine has gained rapid popularity as a treatment option for treatment resistant depression (TRD). Though seen only in limited contexts, ketamine is a potential drug of abuse, addiction and diversion. Clinical ketamine studies to date have not systematically evaluated factors relevant to addiction risk in patients with TRD, but in treating patients with ketamine, risks of potential harms...

Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine

The Journal of Clinical Psychiatry November 14, 2022 Anna Feeney, Bettina B. Hoeppner, Marlene P. Freeman et al. 9 citations

Objective: Ketamine is a novel and rapidly acting treatment for major depressive disorder (MDD). Benzodiazepines are commonly coprescribed with antidepressants in MDD. This study sought to examine data from a randomized clinical trial that compared a single infusion of intravenous (IV) ketamine to midazolam placebo in treatment-resistant depression (DSM-IV-TR MDD) and to assess whether the use...

"K-Powder" Exposure during Adolescence Elicits Psychiatric Disturbances Associated with Oxidative Stress in Female Rats.

Pharmaceuticals November 9, 2022 Sabrina de Carvalho Cartágenes, Cinthia Cristina Sousa de Menezes Da Silveira, Bruno Gonçalves Pinheiro et al.

Ketamine, also called 'K-powder' by abusers, an analog of phencyclidine, primarily acts as an antagonist of N-methyl-D-aspartic acid (NMDA) receptors, therapeutically used as an anesthetic agent. Ketamine also stimulates the limbic system, inducing hallucinations and dissociative effects. At sub-anesthetic doses, ketamine also displays hallucinatory and dissociative properties, but not loss of...

Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.

International Journal of Psychiatry in Clinical Practice November 2022 Ludovic Samalin, Maud Rothärmel, Lila Mekaoui et al.

To present the first real-world data of patients with treatment-resistant depression (TRD) treated with esketamine through a French cohort Temporary Authorisation for Use (ATUc) programme. In 2019, the French Health Authorities exceptionally granted the first ATUc in psychiatry for TRD patients. Clinical characteristics, safety and efficacy data were reported by physicians. The ATUc ended ∼6...

Ketamine as Potential Treatment for Postpartum Depression: A Narrative Review

Annals of Clinical Psychiatry November 1, 2022 David C J Chen-Li, Leanna M.W. Lui, Joshua D. Rosenblat et al. 22 citations

BACKGROUND: Postpartum depression (PPD) is a severe, debilitating mood disorder with consequences for both mothers and children, highlighting the need for rapid-acting and effective treatments for PPD. The aim of this narrative review is to synthesize the available literature on the administration of ketamine for PPD and propose ketamine as a viable and advantageous treatment. METHODS: A search...

DOI: 10.12788/acp.0082 (opens in new tab) Ketamine Depression economics Postpartum depression Psychotherapist +2

The therapeutic role of ketamine and esketamine in treating psychopathological domains of depression.

Neuropharmacology November 1, 2022 Muhammad Youshay Jawad, Joshua D. Di Vincenzo, Sebastian Badulescu et al. 29 citations

Over the past two decades, ketamine has emerged as a novel effective and safe rapid-acting antidepressant. While the vast majority of studies on ketamine have focused on its ability to reduce the severity of depression broadly, its effectiveness in specific domains such as cognition, anhedonia, suicidality, and workplace/social/scholastic functionality has been neglected. Similarly, current...

Maintenance ketamine treatment for depression: a systematic review of efficacy, safety, and tolerability.

The Lancet Psychiatry November 1, 2022 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jan Spijker et al. 163 citations

Ketamine has rapid yet often transient antidepressant effects in patients with treatment-resistant depression. Different strategies have been proposed to prolong these effects. Maintenance ketamine treatment appears promising, but little is known about its efficacy, safety, and tolerability in depression. We searched Pubmed, Embase, and the Cochrane Library and identified three randomised...

Safety of Ketamine Augmentation to Monoamine Oxidase Inhibitors in Treatment-Resistant Depression: A Systematic Literature Review and Case Series.

The Journal of Clinical Psychiatry October 24, 2022 Jolien K E Veraart, Sanne Y Smith-Apeldoorn, M. Kutscher et al.

Objective: Ketamine is increasingly prescribed for treatment-resistant depression (TRD), often as add-on to regular antidepressants. Augmentation of ketamine to monoamine oxidase inhibitors (MAOIs) is advised against, as this practice might increase blood pressure or cause serotonin syndrome. Despite the potential relevance for patients, little is known about actual side effects of combined...